UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) June 27, 2006

DURAVEST, INC

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

FLORIDA		0-27489		65-0924320
(STATE OR OTHER JURISDICTION OF INCORPORATION)		(COMMISSION FILE NUMBER)		(IRS EMPLOYER IDENTIFICATION NUMBER)

101 N. Wacker Drive, Suite 2006, Chicago, IL 60606

(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES, INCLUDING ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (312) 525-8160

(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pro-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8. - Other Events

Item 8.01

Other Events

On June 27, 2006, we issued a press release announcing the appointment of RSM McGladrey, Inc., a business consulting, accounting and tax firm that focuses on mid-sized companies, to provide value calculations for certain intangible assets of our Estracure subsidiary. These value calculations will assist management in complying with the requirements of SFAS 141 in the preparation of our financial statements. A copy of that press release is being filed as an exhibit hereto.

On June 28, 2006, we issued a press release reporting significant progress by our Estracure subsidiary in moving towards a next-generation drug-eluting stent based on 17 beta estradiol. A copy of that press release is being filed as an exhibit hereto.

Section 9. - Financial Statements and Exhibits

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits

Exhibit No.		Description of Exhibits

12(a)		Press Release dated June 27, 2006.

12(b)		Press Release dated June 28, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		DURAVEST, INC.

Dated: June 29, 2006	By:	/s/ Dr. Ogan Gurel
		Dr. Ogan Gurel, President and Chief
		Executive, Officer and a Director

DURAVEST INC 8-K